Wass J A
Department of Endocrinology, St Bartholomew's Hospital Medical College, London, UK.
Horm Res. 1990;33 Suppl 1:1-5; discussion 6.
The experience of St Bartholomew's Hospital in the treatment of acromegaly with octreotide is presented. When administered intravenously and subcutaneously, octreotide had a longer circulating half-life than natural somatostatin. Subcutaneous octreotide in a range of doses (50-400 micrograms) caused a very similar degree of growth hormone (GH) suppression, but the duration of suppression increased with size of dose. A dose of 100 micrograms octreotide 8-hourly provided very good suppression of GH in acromegalic patients; occasional nocturnal escapes may be a problem of inadequate dosage. Long-term octreotide treatment in 14 patients reduced GH to below 20 mU/l and only 1 case was apparently unresponsive. No serious side effects have so far been seen. Octreotide antibodies have been detected in 1 patient unresponsive to octreotide infusion. Gallstones have been found in 6 of 14 patients.
本文介绍了圣巴塞洛缪医院使用奥曲肽治疗肢端肥大症的经验。静脉注射和皮下注射时，奥曲肽的循环半衰期比天然生长抑素更长。一系列剂量（50 - 400微克）的皮下奥曲肽引起的生长激素（GH）抑制程度非常相似，但抑制持续时间随剂量增加而延长。每8小时注射100微克奥曲肽能很好地抑制肢端肥大症患者的GH；偶尔夜间GH水平升高可能是剂量不足的问题。14例患者接受奥曲肽长期治疗后，GH降至20 mU/l以下，仅1例明显无反应。目前尚未观察到严重副作用。在1例对奥曲肽输注无反应的患者中检测到奥曲肽抗体。14例患者中有6例发现胆结石。
